Omnicell, Inc.

What they do

Omnicell provides medication management infrastructure, including storage and dispensing automation, robotics, IV sterile compounding, and an intelligence ecosystem. It sells hardware, software, consumables, and related services, with 90% of revenue from the United States. The company serves hospital and health system solutions and outpatient pharmacy solutions markets, aiming to automate medication workflows from loading dock to bedside.

Revenue drivers

• Connected devices portfolio — Includes automated dispensing systems and robotics; drove Q2 2026 revenue growth across North America and international markets.
• SaaS and Expert Services — Recurring software subscriptions and expert services; increased year-over-year in Q2 2026 and is a strategic focus for recurring revenue.
• Technical services — Maintenance and support services; contributed to Q2 2026 revenue growth and recurring revenue base.
• Consumables — Sales of medication packaging and related consumables; part of the product mix but not separately quantified in provided excerpts.

Recent performance

In Q2 2026 (quarter ended June 30, 2026), total revenues were $312 million, up 7% year-over-year from $290 million in Q2 2025. GAAP net income was $24 million ($0.52 diluted EPS) versus $6 million ($0.12) in the prior-year quarter. Non-GAAP net income was $44 million ($0.94 diluted), and non-GAAP EBITDA was $67 million. The quarter included a $15 million refund of previously paid IEEPA tariffs, which reduced cost of revenues and boosted net income and cash flow. Operating cash flow was $68 million in Q2 2026, compared with $43 million in Q2 2025.

Strategy

Omnicell's strategy centers on advancing the 'Autonomous Pharmacy' vision, combining dispensing automation with an intelligence ecosystem to achieve zero-error medication management. The company is investing in R&D for new solutions, including next-generation platforms like Titan XT and OmniSphere. Management is shifting to flexible payment models—leasing, subscriptions, and as-a-service—to help health systems preserve capital. They are also mitigating tariff impacts through dual-sourcing components and nearshoring manufacturing. Recent leadership changes, including a new President and COO, aim to scale global operations and enhance customer experience.

Risks

• Economic and demand risk — Weak or uncertain economic conditions could reduce demand for capital equipment, and customer creditworthiness or payment delays could hurt results.
• Tariff and supply chain risk — U.S. tariffs on imports from China, Mexico, and Malaysia, and reciprocal tariffs, could raise costs; despite mitigation, future adverse impacts are possible.
• Transition to subscription risk — Selling more products and services on a subscription basis is inherently risky and may not succeed, and maintaining SaaS and Expert Services customers is uncertain.
• Integration of acquisitions — Failure to realize benefits from acquisitions like FDS Amplicare, Omnicell Specialty Pharmacy Services, and others could impair goodwill and other intangible assets.

Outlook

Management updated full-year 2026 guidance, but specific figures were not provided in the excerpts. They expect healthcare providers to prioritize efficiency, safety, and workforce productivity, driving demand for automation and analytics. The company sees a shift from capital expenditures to flexible payment models due to fiscal headwinds from health policy changes like OBBBA and rising input costs. They remain confident in long-term growth opportunities, supported by strong customer interest in next-generation platforms.